youtube_live
Q2 2027 earnings โข released โข Revenue beat +1.47%
See resultschevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
ยฅ4,400.00
arrow_upward
+12.53%(+490.00) 1D
Nov 17, 3:30:00โฏPM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
ยฅ4,040
High
ยฅ4,400
Low
ยฅ4,010
Mkt. cap
204.78B
Avg. vol.
82.43K
Volume
544.20K
Dividend
2.84%
Quarterly dividend
ยฅ31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.31
52-wk high
ยฅ5,040
52-wk low
ยฅ3,500
EPS
ยฅ270
Shares outstanding
46.72M
No. of employees
2K
Open
ยฅ4,040
High
ยฅ4,400
Low
ยฅ4,010
Mkt. cap
204.78B
Avg. vol.
82.43K
Volume
544.20K
Dividend
2.84%
Quarterly dividend
ยฅ31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.31
52-wk high
ยฅ5,040
52-wk low
ยฅ3,500
EPS
ยฅ270
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
ChartMill
·
1 hour ago
S&P 500 Stocks Gapping Down in Today's Session
TradingView
·
1 hour ago
Wells Fargo sets 2027 S&P 500 year-end target at 8,200
Gadget Review
·
1 hour ago
Nearly 10% of the S&P 500 Depends on Just Three Men With No Clear Successors
Traders Union
·
22 minutes ago
S&P 500 trades near AVWAP and key retracement lines, Chris Ciovacco notes
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp